An announcement has been issued by JACOBIO-B (01167) regarding its board of directors' intention to utilize the general mandate granted by shareholders. This mandate, approved at the company's annual general meeting on June 5, 2026, authorizes the board to repurchase up to 10% of the issued shares (excluding treasury shares) as they stood on that date.

The board has resolved to exercise this repurchase authority. Subject to market conditions, the company plans to buy back shares on the open market, allocating up to HKD 1 billion for this purpose.

The funding for this proposed share repurchase will come from the company's own financial resources. It will not utilize the proceeds from its initial listing on the Main Board of The Stock Exchange of Hong Kong Limited. The repurchases will be conducted in a manner that does not materially adversely affect the company's working capital position.

The company reports that all business development and operations are proceeding normally. Multiple core anti-tumor targeted drug candidates are advancing steadily in global clinical trials. Significant external project collaborations continue to be secured, with partnership payments being received as scheduled. The company maintains ample liquid funds on its balance sheet.

The board believes the current share price does not objectively reflect the value of its research pipeline, the prospects for commercialization, or the group's substantial cash reserves. This share repurchase plan is based on the company's fundamentals and long-term development value. It is considered a rational and efficient capital management arrangement that fully demonstrates management's confidence in the pipeline's value and the company's medium- to long-term growth. The board views the plan as being in the overall interests of the company and all its shareholders.